PD-L1-IN-3

SKU: orb2278042

Description

PD-L1-IN-3 is a selective small molecule inhibitor that disrupts the PD-1/PD-L1 protein interaction, thereby blocking immunosuppressive signaling. It is utilized in preclinical cancer immunology research, demonstrating antitumor activity in both cellular assays and in vivo tumor models for neoplasms and autoimmune diseases.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 2953044-29-4
• MW: 373.85
• Purity: 99.58% (May vary between batches)
• Formula: C₁₉H₁₅ClFN₂OS
• SMILES: [Cl].N#CC1=C(OCC2=CC=C(C=C2)CN)SC=C1C=3C=CC(F)=CC3
• Target: PD-1/PD-L1
• Solubility: DMSO:100 mg/mL (267.49 mM)

Bioactivity

• In Vivo:
  In PD-L1+/− (H358 and ES2) tumors, PD-L1-IN-3 (0.01-100 μM; incubation) was observed to exhibit 40-55% higher uptake in PD-L1+ H358 tumors compared to wild-type counterparts. However, it failed to distinguish between wild-type and knockout ES2 samples.
  Read more...
• In Vitro:
  PD-L1-IN-3 (Compound 4a) disrupts the PD-1 and PD-L1 interaction at concentrations of 0.01 to 100 μM over 40 minutes, enhancing TCR-mediated activation of Jurkat cells . Additionally, PD-L1-IN-3 demonstrates increased uptake in PD-L1-positive H358 tumors, proportional to PD-L1 expression levels .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PDL1, PD-L1, PD1/PDL1, PD-1, PD1

Compound Identifiers

PubChem CID

168510313